2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

Aapro, Matti; Bohlius, Julia; Cameron, David; Lago, Lissandra Dal; Donnelly, J. Peter; Kearney, Nora; Lyman, Gary H.; Pettengell, Ruth; Tjan-Heijnen, V. C. G.; Walewski, Jan; Weber, Damien Charles; Zielinski, C.

doi:10.1016/j.ejca.2010.10.013

Cited by 983 publications

(1,050 citation statements)

References 217 publications

Supporting

Mentioning

957

Contrasting

Unclassified

Order By: Relevance

“…Serious neutropenia will cause chemotherapy delay, chemotherapy reduction or chemotherapy related infection was also increased (Aapro et al, 2011). But the severe neutropenia did not appear in our research.…”

Section: Discussioncontrasting

confidence: 55%

Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil

Bu¹,

Cheng²,

Gao³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Purpose: To investigate the efficacy and safety of selective radiotherapy after distant metastasis of nasopharyngeal carcinoma (NPC) treated with dose-dense cisplatin plus fluorouracil. Materials and Methods: Eligible patients were randomly assigned to a study group treated with dose-dense cisplatin plus fluorouracil following selective radiotherapy and a control group receiving traditional cisplatin plus fluorouracil following selective radiotherapy according to a 1:1 distribution using a digital random table method. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival (PFS), objective response rate, relapse or progression rate in the radiation field and treatment toxicity. Results: Of 52 patients in the study group, 20 cases underwent radiotherapy., while in the control group of 51 patients, 16 underwent radiotherapy. The median PFS, median OS, survival rates in 1, 2 and 3 years in study and control group were 20.9 vs 12.7months, 28.3 vs 18.8months, 85.2%vs 65.9%, 62.2% vs 18.3%, and 36.6%vs 5.2% (p values of 0.00, 0.00, 0.04, 0.00 and 0.00, respectively). Subgroup analysis showed that the median OS and survival rates of 1, 2, 3 years for patients undergoing radiotherapy in the study group better than that in control group( 43.2vs24.1 months, 94.1% vs 86.7%, 82.4% vs 43.3%, 64.7% vs 17.3%, (p=0.00, 0.57, 0.04 and 0.01, respectively). The complete response rate, objective response rate after chemotherapy and three months after radiotherapy, relapse or progression rate in radiation field in study group and in control group were 19.2% vs 3.9%, 86.5% vs 56.9%, 85% vs 50%, 95% vs 81.3% and 41.3% vs 66.7% (p =0.03, 0.00, 0.03,0.30, 0.01 respectively). The grade 3-4 acute adverse reactions in the study group were significantly higher than in the control group (53.8% vs 9.8%, p=0.00). Conclusions: The survival of patients benefits from selective radiotherapy after distant metastasis of NPC treated with dose-dense cisplatin plus fluorouracil.

show abstract

Section: Discussioncontrasting

confidence: 55%

Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil

Bu¹,

Cheng²,

Gao³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Although clinical guidelines3, 4, 5, 6 recommend consideration of patient‐level risk factors when making G‐CSF prophylaxis decisions, it is not clear how prophylaxis should be best directed based on the presence of these patient‐level risk factors. A risk prediction model incorporating all relevant patient‐level risk factors is thus needed to guide prophylactic decisions.…”

Section: Discussionmentioning

confidence: 99%

“…The following FN risk categories were considered in the reclassification analysis described above: <5%, 5% to <10%, and ≥10%. These ranges were chosen as it has been reported that approximately half of FN events occur in the first chemotherapy cycle;3, 17 therefore, they are likely equivalent to approximately <10%, 10% to 20%, and >20% FN risk over the chemotherapy course, which are cutoffs used in clinical guidelines 3, 4, 5, 6…”

Section: Methodsmentioning

confidence: 99%

“…Risk of developing FN is affected by chemotherapy regimens, patient characteristics, and disease characteristics. Clinical guidelines recommend primary prophylaxis with granulocyte colony‐stimulating factor (G‐CSF) in patients receiving high‐risk chemotherapy regimens (>20% risk in a chemotherapy course) and recommend consideration of G‐CSF prophylaxis for patients receiving intermediate‐risk chemotherapy regimens (10%‐20% risk in a chemotherapy course) who have additional risk factors 3, 4, 5, 6. Therefore, FN risk prediction tools incorporating patient and disease characteristics for individual patients could inform the clinical use of G‐CSF.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Value of incorporating newly identified risk factors into risk prediction for chemotherapy‐induced febrile neutropenia

Family

Chen

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

Several comorbidities have recently been shown to affect risk of chemotherapy‐induced febrile neutropenia (FN). Here, we evaluated the added predictive value of these comorbidities beyond established FN risk factors. A retrospective cohort study was conducted among adult patients diagnosed with cancer and treated with chemotherapy at Kaiser Permanente Southern California between 2000 and 2009. The study cohort was equally split into training and validation datasets to develop and evaluate the performance of FN risk prediction models in the first chemotherapy cycle. A reference model was developed based on the model proposed by Lyman et al (Cancer 2011;117:1917). A new model was developed by incorporating the newly identified comorbidities such as rheumatoid conditions and thyroid disorders into the reference model. Area under the receiver operating characteristic curve (AUROCC), risk reclassification, and integrated discrimination improvement (IDI) were used to evaluate the potential improvement of FN risk prediction by incorporating comorbidities. A total of 15 279 patients were included; 4.2% experienced FN in the first chemotherapy cycle. Including comorbidities in FN risk prediction did not improve AUROCC (reference model 0.71 vs new model 0.72). A significant improvement in individual‐level FN risk prediction was indicated by IDI (P = .02). However, significant improvement in risk reclassification was not observed overall (although 6% of all patients were more accurately classified for their FN risk level, 5% were less accurately classified) or when examining predicted FN risk among patients who did and did not develop FN. Incorporating several new comorbidities into FN prediction led to improved FN risk prediction in the first chemotherapy cycle, although the observed improvements were small and might not be clinically relevant.

show abstract

“…G-CSF use is likely to have been reactive rather than prophylactic [25]. The median duration of daily G-CSF use was only one day, indicating it was generally administered as short courses or intermittent doses during a cycle.…”

Section: Discussionmentioning

confidence: 99%

An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR‐MM)

et al. 2016

View full text Add to dashboard Cite

Neutropenia is a well‐known dose‐limiting toxicity associated with lenalidomide plus dexamethasone treatment in patients with multiple myeloma; however, little is known about its management and associated outcomes in the real world setting. The present prospective, multicenter, observational study evaluated the incidence, management, and outcomes of grade 3/4 neutropenia in patients with relapsed or relapsed/refractory multiple myeloma who initiated treatment with lenalidomide plus dexamethasone. Of 198 patients, 62 (31%, 95% CI: 25, 38) experienced grade 3/4 neutropenia, and half of these patients experienced 3 or more events during the 12‐month observational period. Grade 3/4 neutropenia occurred throughout lenalidomide treatment, with a median time to first event of 8.8 weeks (Q1, Q3: 5.9, 17.3). In a multivariate analysis, diagnosis of relapsed and refractory disease was associated with grade 3/4 neutropenia. Lenalidomide exposure reduction, use of G‐CSF, unplanned hospitalization, and outpatient clinic visits were more common in patients who experienced grade 3/4 neutropenia than in those who did not. In conclusion, grade 3/4 neutropenia is a common toxicity and patients are at continued risk throughout treatment with lenalidomide and dexamethasone. Further efforts should be made to improve the recommendations for neutropenia management in this population. Am. J. Hematol. 91:806–811, 2016. © 2016 Wiley Periodicals, Inc.

show abstract

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

Cited by 983 publications

References 217 publications

Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil

Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil

Value of incorporating newly identified risk factors into risk prediction for chemotherapy‐induced febrile neutropenia

An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR‐MM)

Contact Info

Product

Resources

About